IPO - Ocugen, Inc.

Form Type: S-3

Filing Date: 2025-01-31

Corporate Action: Ipo

Type: New

Accession Number: 000110465925008108

Filing Summary: Ocugen, Inc. filed a registration statement on Form S-3 with the SEC to offer and sell up to 57,542,768 shares of its common stock, primarily associated with a recent Loan and Security Agreement dated November 6, 2024. This agreement involved significant financial backing from Avenue Capital Management and its funds, allowing for the conversion of $6 million of principal into shares of common stock at a price equal to 80% of the trading price on the date of conversion. The filing highlights that the company will not receive any proceeds from the resale of these shares by the selling stockholders, who include lenders and their affiliates. Ocugen's common stock trades on the Nasdaq under the ticker symbol 'OCGN'. The company is positioned as a biotechnology firm focused on gene and cell therapies, particularly in retinal diseases, showcasing its research initiatives and clinical trial progress in several promising therapeutic areas. The prospectus outlines investment risks and includes necessary legal disclaimers about the securities' offering and potential market effects.

Document Link: View Document